New Co-Pay Assistance Program for Homozygous Familial Hypercholesterolemia Patients

Monday, November 2, 2015

HAMPTON, VA -- The Co-Pay Relief (CPR) program, a division of Patient Advocate Foundation (PAF) providing pharmaceutical co-payment assistance to qualified insured patients, is pleased to announce the opening of a new fund benefiting those with Homozygous Familial Hypercholesterolemia, commonly referred to as HoFH. 

HoFH is a rare but severe genetic disorder that makes the liver incapable of metabolizing cholesterol, leading to aggressive atherosclerosis. Without the option of pharmaceutical therapies, patients face dialysis to remove cholesterol from their blood and eventual liver transplant. If left untreated, individuals will usually experience heart attacks by the time they reach their early twenties.

The opening of this fund reaffirms Patient Advocate Foundation’s commitment to serving vulnerable populations, including those with rare diseases. “Providing patients with rare disorders financial relief for their treatment options is a critical component of the Co-Pay Relief program,” Fran Castellow MSED, President of Operations for PAF says.

“Patients with rare diseases often see limited treatment options and may incur much higher costs,” CEO Alan Balch, PhD of PAF adds. “The new fund will provide HoFH patients with financial relief to help alleviate the economic burden associated with pharmaceutical co-payments that the diagnosis of a serious illness often causes.”

The HoFH co-payment financial assistance fund provides direct financial support for pharmaceutical expenses related to treatment and management of Homozygous Familial Hypercholesterolemia (HoFH). Approved patients are eligible for up to $15,000 in fully guaranteed available assistance per award year.

The HoFH fund will begin accepting applications from financially and medically qualified individuals on Monday, November 2, 2015. Those interested in applying for help should contact a PAF Co-Pay Relief specialist at 1-866-512-3861 or visit